日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

Sinopharm subsidiary: Full clinical trial data submitted

By WANG XIAOYU | CHINA DAILY | Updated: 2021-06-22 07:25
Share
Share - WeChat
A nurse holds a syringe containing a coronavirus disease (COVID-19) vaccine made by the Beijing Institute of Biological Products, a unit of Sinopharm subsidiary China National Biotec Group (CNBG), at a vaccination center during a visit, in Beijing, April 15, 2021. [Photo/Agencies]

Zhang Yuntao, vice-president of China National Biotech Group, a subsidiary of Sinopharm, said the company has submitted complete and detailed clinical trial data on its COVID-19 vaccines to the World Health Organization and other countries, which reviewed its vaccines for emergency use.

The company has never withheld underlying data on clinical trials on two COVID-19 vaccines developed by two institutions under CNBG, he said.

"On Dec 28, we submitted a full set of data on the inactivated vaccine from the Beijing Institute of Biological Products to the National Medical Products Administration. On Dec 30, the administration and our official website both published the key information on the vaccine's efficacy rate, which is 79.34 percent," he said.

The Beijing Institute vaccine was the first to receive conditional approval from China's top drug regulator. In May, the WHO approved the vaccine for emergency use.

Before both CNBG vaccines were administered to people overseas, Zhang said national drug regulators had access to "full data and material" on clinical trials before they were granted approval.

On May 26, a study published in The Journal of the American Medical Association, a global peer-reviewed publication, showed that both vaccines had an efficacy rate of more than 70 percent.

Zhang added that the company held itself to high standards during human trials and analysis of results, focusing on core data that revealed both vaccines' effectiveness in preventing people from getting symptomatic COVID-19 diseases. The efficacy rate is the most crucial determinant of whether herd immunity can be built, he added.

When using the efficacy rate as the sole barometer, CNBG's vaccines appear to be at a disadvantage compared with mRNA vaccines made by Pfizer/BioNTech and Moderna in developed countries, which both have reported efficacy rates higher than 90 percent, he said.

"I think the difference in the efficacy rate stems from the different technologies that are used in developing these vaccines," he said. CNBG's vaccines are made through the more established method of using an inactivated virus to trigger immune responses.

"But all vaccines have strengths and weaknesses. Assessing a vaccine product should take the likelihood of adverse reactions and its accessibility to the general public into consideration as well," he said.

On April 21, CNBG released safety data on large-scale emergency use of its COVID-19 vaccines delivered to nearly 520,000 Chinese. Results have shown that the rate of adverse reactions following inoculation is lower than that of other common inactivated vaccines, such as those preventing hepatitis A and influenza.

Another trademark of CNBG's vaccines is that they can be stored and transported at temperatures of 2 to 8 C, rather the very cold temperatures required for mRNA vaccines.

The company is also keeping a close eye on how long immunity lasts, the role of booster shots and threats from variants circulating overseas.

Zhang said clinical trials designed to address these concerns were already underway, such as injecting a third shot to boost immune response that can last longer or can fend off new coronavirus strains.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 激情五月色播 | 国产www色 | 国产视频一二区 | 成人午夜大片 | 亚洲国产成人精品女人 | 国产精品2区 | 中文字幕视频在线观看 | 亚洲天堂在线电影 | 成人免费毛片片v | 激情做a全过程片A | 日韩免费视频网站 | 亚洲免费三区 | 午夜18禁A片兔费看 四虎影视在线看免费完整版 | a级在线观看免费 | 天天草人人草 | 亚洲欧美日韩精品久久 | 久操久操 | 久久精品夜夜夜夜夜久久 | 欧美人两个人激情的免费视频 | 欧美大片在线看免费观看 | 国产精品免费一区二区三区都可以 | 嫩草影院在线看 | 欧美三区在线 | 久热在 | 亚洲精品第一综合99久久 | 国产一区二区三区免费 | 草草国产成人免费视频 | 亚洲国产午夜电影在线入口 | 一级片免费 | 十六以下岁女子毛片免费 | 欧美国产日本高清不卡 | 91久久精品一区二区二区 | 影音先锋中文字幕在线 | 国产在线精品一区二区三区 | 精品96久久久久久中文字幕无 | 国产区精品在线 | 九九热精品在线视频 | 91在线精品秘密一区二区 | 国产一区二区三区乱码 | 欧美午夜一区 | 成人免费久久精品国产片久久影院 |